{"id":"rosiglitazone-alpha-lipoic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Fluid retention / edema"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL134342","moleculeType":"Small molecule","molecularWeight":"206.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosiglitazone is a thiazolidinedione that enhances insulin sensitivity in peripheral tissues and reduces hepatic glucose production. Alpha-lipoic acid is a naturally occurring antioxidant that may improve mitochondrial function and glucose utilization. The combination is intended to provide complementary metabolic benefits for glycemic control and potentially reduce insulin resistance through dual mechanisms.","oneSentence":"Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while alpha-lipoic acid acts as an antioxidant to reduce oxidative stress and improve glucose metabolism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:06:01.432Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT00948324","phase":"PHASE4","title":"Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes","status":"SUSPENDED","sponsor":"Sun Yat-sen University","startDate":"2008-06","conditions":"Type 2 Diabetes Mellitus","enrollment":400},{"nctId":"NCT01406704","phase":"PHASE4","title":"Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH","status":"TERMINATED","sponsor":"Seoul St. Mary's Hospital","startDate":"2004-01","conditions":"NASH (Non-alcoholic Steato-hepatitis)","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avandia/Thioctic acid"],"phase":"marketed","status":"active","brandName":"Rosiglitazone/alpha-lipoic acid","genericName":"Rosiglitazone/alpha-lipoic acid","companyName":"Seoul St. Mary's Hospital","companyId":"seoul-st-mary-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while alpha-lipoic acid acts as an antioxidant to reduce oxidative stress and improve glucose metabolism. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}